A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Azacitidine / therapeutic use
  • Humans
  • Leukemia, Myelomonocytic, Chronic* / complications
  • Leukemia, Myelomonocytic, Chronic* / drug therapy
  • Myelodysplastic Syndromes* / complications
  • Myelodysplastic Syndromes* / drug therapy
  • Prospective Studies
  • Steroids

Substances

  • Azacitidine
  • Steroids